Previous close | 0.9500 |
Open | 0.9500 |
Bid | 0.0000 |
Ask | 1.6000 |
Strike | 2.50 |
Expiry date | 2024-10-18 |
Day's range | 0.9500 - 0.9500 |
Contract range | N/A |
Volume | |
Open interest | 13 |
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a melanocortin 4 receptor (MC4R) agonist, co-administered with tirzepatide (GLP-1/GIP) in obese patients. The primary endpo
Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Despite a dip in product sales, PTN progresses in clinical developments and maintains a stable financial footing.